12 Health Care Stocks Moving In Wednesday's After-Market Session

Benzinga · 3d ago
Gainers
- Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million.
- Profound Medical (NASDAQ:PROF) stock rose 16.98% to $6.64. The market value of their outstanding shares is at $222.1 million.
- China Pharma Holding (AMEX:CPHI) stock rose 15.84% to $0.98. The market value of their outstanding shares is at $27.5 million.
- Quoin Pharmaceuticals (NASDAQ:QNRX) shares moved upwards by 10.86% to $5.0. The company's market cap stands at $9.4 million.
- Dyadic International (NASDAQ:DYAI) shares increased by 7.29% to $0.49. The market value of their outstanding shares is at $18.1 million.
- Kairos Pharma (AMEX:KAPA) shares moved upwards by 6.81% to $0.93. The company's market cap stands at $3.8 million.
Losers
- Medicus Pharma (NASDAQ:MDCX) stock fell 30.0% to $0.11 during Wednesday's after-market session. The market value of their outstanding shares is at $11.4 million.
- China SXT Pharmaceuticals (NASDAQ:SXTC) stock decreased by 16.97% to $2.35.
- Lexaria Bioscience (NASDAQ:LEXX) stock decreased by 10.41% to $3.1. The market value of their outstanding shares is at $6.8 million.
- NexGel (NASDAQ:NXGL) stock decreased by 9.71% to $0.16. The market value of their outstanding shares is at $1.6 million.
- Evogene (NASDAQ:EVGN) shares declined by 6.97% to $0.38. The market value of their outstanding shares is at $5.1 million.
- MDxHealth (NASDAQ:MDXH) stock declined by 6.64% to $0.56. The company's market cap stands at $57.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.